Blood Flow to Brain Function: How GLP-1 Therapies May Reduce Dementia Risk GLP-1 receptor agonists have emerged as one of the most promising pharmacologic classes for reducing dementia risk, supported by converging evidence from mechanistic studies, large observational cohorts, and early clinical trials
Hyperhomocysteinemia induced by folic acid deficiency and methionine load Applications of a modified HPLC method
This includes: When does your headache start, and how long does it last
When you engage in physical activities, your body taps into its fat stores for fuel
Exclusion criteria for all groups included current or previous psychiatric comorbidities as diagnosed by DSM-5, using a structured interview (The Structured Clinical Interview for DSM-5, SCID-5) [28] if deemed relevant by the investigator, any general medical conditions known to influence energy processing and/or linked to fatigue, current treatment with any medication/supplementation likely to interfere with energy metabolism if deemed relevant by the investigator, contra-indications to magnetic resonance (MR) imaging, pregnancy or breast feeding
